CANLI
Yükleniyor Veriler getiriliyor…
/ Makaleler / Scopus Detay
Scopus YÖKSİS DOI Eşleşti SJR Q1

Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions

Urologic Oncology Seminars and Original Investigations · Mart 2025

Özet
Introduction: The objective of this study is to predict the probability of prostate cancer in PI-RADS 3 lesions using machine learning methods that incorporate clinical and mpMRI parameters. Methods: The study included patients who had PI-RADS 3 lesions detected on mpMRI and underwent fusion biopsy between January 2020 and January 2024. Radiological parameters (Apparent diffusion coefficient (ADC), tumour ADC/contralateral ADC ratio, Ktrans value, periprostatic adipose tissue thickness, lesion size, prostate volume) and clinical parameters (age, body mass index, total prostate specific antigen, free PSA, PSA density, systemic inflammatory index, neutrophil-lymphocyte ratio [NLR], platelet lymphocyte ratio, lymphocyte monocyte ratio) were documented. The probability of prostate cancer prediction in PI-RADS 3 lesions was calculated using 6 different machine-learning models, with the input parameters being the aforementioned variables. Results: Of the 235 participants in the trial, 61 had malignant fusion biopsy pathology and 174 had benign pathology. Among 6 different machine learning algorithms, the random forest model had the highest accuracy (0.86±0.04; 95% CI 0.85–0.87), F1 score (0.91±0.03; 95% CI 0.91–0.92) and AUC value (0.92±0.06; 95% CI 0.88–0.90). In SHAP analysis based on random forest model, tumour ADC, tumour ADC/contralateral ADC ratio and PSA density were the 3 most successful parameters in predicting malignancy. On the other hand, systemic inflammatory index and neutrophil lymphocyte ratio showed higher accuracy in predicting malignancy than total PSA, age, free PSA/total PSA and lesion size in SHAP analysis. Conclusion: Among the machine learning models we developed, especially the random forest model can predict malignancy in PI-RADS 3 lesions and prevent unnecessary biopsy. This model can be used in clinical practice with multicentre studies including more patients.
6 atıf Mart 2025 DOI
YÖKSİS DOI Eşleşmesi Bulundu

Bu Scopus makalesi YÖKSİS veritabanında da kayıtlı. Aşağıda YÖKSİS verilerini görebilirsiniz.

YÖKSİS Kayıtları
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Prof. Dr. MEHMET KAYNAR →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Prof. Dr. MEHMET KAYNAR →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Doç. Dr. EMRE ALTINTAŞ →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2024 SCI-Expanded
Doç. Dr. EMRE ALTINTAŞ →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Doç. Dr. MURAT GÜL →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Prof. Dr. ÖZCAN KILIÇ →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Prof. Dr. SERDAR GÖKTAŞ →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Dr. Öğr. Üyesi SEYİT EROL →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Doç. Dr. HALİL ÖZER →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
Urologic Oncology: Seminars and Original Investigations · 2025 SCI-Expanded
Doç. Dr. ALİ FURKAN BATUR →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 20 kaydı bulundu.
Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer
2023 ISSN: 1078-1439 SCI
Prof. Dr. ZELİHA ESİN ÇELİK →
Predictive value of the HAS-BLED score in the course of radical cystectomy: A pilot study
2026 ISSN: 1078-1439 SCI-Expanded Q1
Dr. Öğr. Üyesi AHMET GÖRGEL →
Neutrophil to lymphocyte ratio predicts progression and recurrence of non muscle invasive bladder cancer
2015 ISSN: 10781439 SSCI
Prof. Dr. SERDAR GÖKTAŞ →
Neutrophil to lymphocyte ratio predicts progression and recurrence of non muscle invasive bladder cancer
2015 ISSN: 10781439 SCI
Prof. Dr. MEHMET KAYNAR →
Association of ring box-1 protein overexpression with clinicopathologic prognostic parameters in prostate carcinoma
2016 ISSN: 10781439 SCI-Expanded
Prof. Dr. ZELİHA ESİN ÇELİK →
Association of ring box 1 protein overexpression with clinicopathologic prognostic parameters in prostate carcinoma
2016 ISSN: 10781439 SCI
Prof. Dr. MEHMET KAYNAR →
Association of ring box 1 protein overexpression with clinicopathologic prognostic parameters in prostate carcinoma
2016 ISSN: 10781439 SCI-Expanded
Prof. Dr. MEHMET KAYNAR →
Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer
2019 ISSN: 1078-1439 SCI-Expanded
Prof. Dr. MEHMET KAYNAR →
Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer
2019 ISSN: 1078-1439 SCI-Expanded Q3
Prof. Dr. ÖZCAN KILIÇ →
Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer
2020 ISSN: 1078-1439 SSCI
Prof. Dr. MEHMET KAYNAR →
Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer
2020 ISSN: 1078-1439 SCI-Expanded Q2
Doç. Dr. EMRE ALTINTAŞ →
Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer
2023 ISSN: 1078-1439 SCI-Expanded Q2
Doç. Dr. MURAT GÜL →
Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer
2023 ISSN: 1078-1439 SCI-Expanded Q2
Prof. Dr. ZELİHA ESİN ÇELİK →
Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer
2023 ISSN: 1078-1439 SCI-Expanded Q2
Doç. Dr. EMRE ALTINTAŞ →
Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer
2023 ISSN: 1078-1439 SCI-Expanded Q2
Prof. Dr. SERDAR GÖKTAŞ →
Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer
2023 ISSN: 1078-1439 SCI-Expanded Q2
Doç. Dr. ALİ FURKAN BATUR →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
2025 ISSN: 1078-1439 SCI-Expanded Q2
Prof. Dr. MEHMET KAYNAR →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
2025 ISSN: 1078-1439 SCI-Expanded Q2
Doç. Dr. EMRE ALTINTAŞ →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
2025 ISSN: 1078-1439 SCI-Expanded Q2
Prof. Dr. SERDAR GÖKTAŞ →
Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions
2025 ISSN: 1078-1439 SCI-Expanded Q2
Dr. Öğr. Üyesi SEYİT EROL →

Makale Bilgileri

Toplam Atıf 6 atıf · Scopus
ISSN10781439
Yayın TarihiMart 2025
Cilt / Sayfa43 · 195-195.e20

Kurumlar

Selçuk Üniversitesi
Selçuklu Turkey

Havuzumuzdaki Atıflar 0

Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 6.

Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi (ISSN Eşleşmesi)
Urologic Oncology: Seminars and Original Investigations
Q1
SJR Skoru0,997
H-Index93
YayıncıElsevier Inc.
ÜlkeUnited States
Urology (Q1)
Oncology (Q2)
Dergi sayfasına git

Metrikler

6
Atıf

Sistemimizdeki Yazarlar